Home > What's New > Archive > Advanced Cell Diagnostics, Inc. Webinar @September 14, 2021(Tue)
Advanced Cell Diagnostics, Inc. Webinar @September 14, 2021(Tue)
2021-08-25 09:13:09 Source：Gene Company Limited
Advanced Cell Diagnostics, Inc. Webinar @September 14, 2021(Tue), Time: 11:00 p.m. (HKT)
Spatial analysis for visualizing small RNA species implicated in disease and development
Outline:
The RNAscope™ in situ hybridization (ISH) technology provides a powerful method to detect gene expression within the spatial and morphological tissue context. The proprietary probe design in combination with advanced signal amplification enables robustly high signal-to-noise and allows for the detection of gene transcripts at the single molecule level with single-cell resolution.
Now, this webcast will present the miRNAscope™ Assay, an advanced in situ hybridization platform that allows for highly specific and sensitive visualization of small RNA species expression with single-cell resolution.
Learning Objectives:
- The miRNAscope technology and workflow
- Detecting miRNAs implicated in cancer and distinguishing multiple members from the same family
- Functional information provided by identifying cell-type specific miRNAs in the brain
- Visualizing synthetic oligonucleotides such as small interfering RNAs (siRNAs) and anti-sense oligonucleotides (ASOs) that can target specific genes and regulate their expression
SPEAKER:
Anushka Dikshit, Ph.D.
Sr. Scientist, Supervisor, Applications, Genomics, Advanced Cell Diagnostics
Gene Company Ltd is the sole distributor of Advanced Cell Diagnostics, Inc. in HK and Macau.
ADVANCED TECHNOLOGY FOR SMALL RNA RESEARCH AND OLIGONUCLEOTIDE THERAPEUTICS DEVELOPMENT
The revolutionary new miRNAscope™ Assay is highly specific and sensitive. Advances in drug development utilizing antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) as therapeutic platforms bring promising solutions for various diseases in the field of precision medicine. The ability to visualize the oligonucleotide drug in intact tissues with high sensitivity and specificity is crucial to evaluate their therapeutic safety and efficacy.
The miRNAscope Assay demonstrates exceptional performance for the detection of:
• Antisense oligonucleotides (ASOs) • Small interfering RNAs (siRNAs)
• microRNAs (miRNAs) • Small RNA sequences that are 17-50nt in length
VISUALIZE SMALL OLIGOS AT THE SINGLE-CELL LEVEL WITH UNMATCHED RESOLUTION
• Evaluate delivery strategies for RNA therapeutics
• Study biodistribution
• Assess efficacy of therapy
• Screen for potential off-target effects
ASO
ASOs are used as therapeutic solutions for mod- ulating disease processes by altering synthesis of a specific protein.
Example detection of ASO target (yellow arrows) in the treat- ed mouse quad muscle tissue samples and not in the vehicle
samples indicates successful delivery of ASO therapy.
Note: Above tissue slides were counterstained with hematoxylin to provide blue staining of cells.
siRNA
siRNAs are being developed as potential thera- peutic agents by silencing specific gene targets.
Example of specific detection of the siRNA#1 probe (yellow arrows) in siRNA#1 treated mouse liver tissue samples only and not in the negative saline nor siRNA#2 treated samples indicates success- ful delivery of siRNA therapy and specificity of the miRNAscope Assay. Biodistribution of siRNA target is also observed in the siRNA#1 treated samples.